Review: taking Trileptal and Implanon together


Summary

Drug interactions are reported among people who take Trileptal and Implanon together. This review analyzes the effectiveness and drug interactions between Trileptal and Implanon. It is created by eHealthMe based on reports of 24 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Trileptal

Trileptal has active ingredients of oxcarbazepine. It is often used in epilepsy. (latest outcomes from Trileptal 15,601 users)

Implanon

Implanon has active ingredients of etonogestrel. It is often used in birth control. (latest outcomes from Implanon 8,977 users)

On Sep, 19, 2016

24 people who take Trileptal, Implanon are studied.


Number of reports submitted per year:

Trileptal and Implanon drug interactions.

Drug effectiveness over time:

Trileptal:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 100.0% - (1 of 1 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Implanon:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Trileptal:
  • female: 75.0% - (3 of 4 people)
  • male: 0.0% - (0 of 0 people)
Implanon:
  • female: 100.0% - (3 of 3 people)
  • male: 0.0% - (0 of 0 people)

Drug effectiveness by age:

Trileptal:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 66.0% - (2 of 3 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)
Implanon:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 100.0% - (3 of 3 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

1 - 6 months:
  • dizziness
  • nausea
  • swelling of the ankles - feet - legs
  • capillary disorder
  • convulsion
  • headache
  • hives
  • inflammation
  • labile affect
  • pain in extremity
6 - 12 months:
  • pregnancy
  • menorrhagia
  • headache
1 - 2 years:
  • headache
  • hives
  • labile affect
2 - 5 years:
  • headache
  • medical device complication
  • pregnancy
  • migraine
  • surgery
  • weight increased
not specified:
  • menstruation irregular
  • drug administration error
  • medical device complication
  • unintended pregnancy
  • menorrhagia
  • oropharyngeal pain
  • therapeutic response unexpected
  • abdominal pain
  • abortion induced
  • adverse event

Most common drug interactions by gender *:

female:
  • medical device complication
  • headache
  • menstruation irregular
  • drug administration error
  • dizziness
  • menorrhagia
  • nausea
  • pregnancy
  • swelling of the ankles - feet - legs
  • unintended pregnancy

Most common drug interactions by age *:

10-19:
  • medical device complication
  • menstruation irregular
  • abdominal pain
  • hives
  • implant site erythema
  • medical device discomfort
  • menstruation normal
  • mood swings
  • seizure
  • surgery
20-29:
  • headache
  • dizziness
  • menorrhagia
  • nausea
  • pregnancy
  • swelling of the ankles - feet - legs
  • drug administration error
  • labile affect
  • menstruation irregular
30-39:
  • drug administration error
  • oropharyngeal pain
  • therapeutic response unexpected
  • capillary disorder
  • convulsion
  • inflammation
  • pain in extremity
40-49:
  • abortion induced
  • drug exposure during pregnancy
  • unintended pregnancy

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Trileptal and Implanon?

Can you answer these questions?

More questions for: Trileptal, Implanon

You may be interested in these reviews

More reviews for: Trileptal, Implanon

On eHealthMe, Trileptal (oxcarbazepine) is often used to treat epilepsy. Implanon (etonogestrel) is often used to treat birth control. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.